Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Multimodal “4D”-therapy of pediatric high grade glioma

Project description

Multimodal treatment for malignant brain tumour in children

Paediatric high-grade glioma is the most common malignant brain tumour in children. Standard treatments often fall short, and new combination therapies are urgently needed, yet current options have done little to improve outcomes. The ERC-funded 4D-therapy project aims to create a targeted multimodal treatment for pHGG. It will combine drug therapies, radiotherapy, and innovative gene therapies to enhance treatment effectiveness and reduce side effects. The project will include initial screening and validation of a novel treatment regimen, detailed molecular profiling, and the use of adeno-associated viruses and CRISPR technology for precise targeting. Ultimately, it will establish effective treatment protocols for pHGG and provide insights into multimodal cancer therapy through preclinical studies with patient-derived models.

Objective

Paediatric high grade glioma (pHGG) is the most common malignant childhood brain tumour with standard-of-care inevitably resulting in therapy-resistant relapse or disease progression. The need for new combinatorial treatments is universally acknowledged; however, modern combination therapies are sparse, include at most two modalities and have so far not been able to significantly improve the dismal prognosis of the disease.
In this proposal, I conceptualize a highly targeted multimodal treatment strategy for pHGG (4D-therapy) based on complementary precision medicine approaches. The system leverages multiple inter-modal synergies, overcomes resistance to individual therapies and disperses off-targeting to different cell populations, thereby creating a large therapeutic window.
Initially, we will conduct a comprehensive screen to evaluate a novel regimen of combined upfront targeted drug- and radiotherapy (RT), followed by functional validation in vitro and in vivo. In-depth molecular profiling will allow us to unravel mechanisms of radiosensitization.
Further, we aim to establish an innovative gene therapy approach with unprecedented, highly specific tropism for tumour cells by combining elaborately selected adeno-associated viruses and nanocapsules with newly identified Cas-nucleases.
Ultimately, we will systematically combine drug-RTs, gene therapies and existing tumour-specific CAR-T cells within a rationally designed, multimodal treatment regimen and evaluate its efficacy in a series of preclinical studies. A broad representation of patient-derived xenografts, complemented by immunocompetent allograft models will provide leading-edge predictive power and a unique dataset to investigate multimodal interactions.
I expect this project to provide pioneering insights into inter-modal treatment synergies, to produce stratified treatment protocols for pHGG, directly informing clinical trials and to become a pathbreaking feasibility study for multimodal cancer therapy.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-STG

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 1 493 711,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 1 493 711,00

Beneficiaries (1)